Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MVD | P53602 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25129552 | 0.97 | MEN1 (0.46) | MEN1GAAKMT2ATDP1CKS1B | |
| SCHEMBL25235106 | 0.90 | TDP1 (0.57) | MEN1GAAKMT2ATDP1CKS1B | |
| SCHEMBL13055395 | 0.88 | TDP1 (0.55) | MEN1GAAKMT2ATDP1CKS1B | |
| SCHEMBL18429539 | 0.87 | MEN1 (0.49) | MEN1GAAKMT2ATDP1CKS1B | |
| SCHEMBL20968689 | 0.85 | TDP1 (0.46) | MEN1GAAKMT2ATDP1CKS1B | |
| SCHEMBL24029924 | 0.85 | TDP1 (0.46) | MEN1GAAKMT2ATDP1CKS1B | |
| SCHEMBL29239019 | 0.85 | MEN1 (0.50) | MEN1GAAKMT2ATDP1CKS1B | |
| SCHEMBL3167773 | 0.85 | MEN1 (0.50) | MEN1GAAKMT2ATDP1CKS1B | |
| SCHEMBL25531030 | 0.83 | TDP1 (0.50) | MEN1GAAKMT2ATDP1CKS1B | |
| SCHEMBL5019159 | 0.81 | MEN1 (0.48) | MEN1GAAKMT2ATDP1CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331760-A1 | ARYL GLUCOSIDE DERIVATIVE AND USE THEREOF IN DRUG | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| EP-3130608-B1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10036066-B2 | In situ hybridization detection method | DAKO DENMARK A/S (DK) | 2018-07-31 | — | — | US | disclosed |
| US-9598720-B2 | Monomeric and polymeric linkers useful for conjugating biological molecules and other substances | DAKO DENMARK A/S (DK) | 2017-03-21 | — | — | US | disclosed |
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20160273035-A1 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
| WO-2007031874-A2 | METHOD OF SIMULTANEOUSLY VISUALIZING MULTIPLE BIOLOGICAL TARGETS | DAKO DENMARK A/S (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007026252-A2 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK A/S (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007023390-A2 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | DAKO DENMARK A/S (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1757609-A1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1757609-A1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007015168-A2 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | DAKO DENMARK A/S (US) | 2007-02-08 | — | — | WO | disclosed |
| EP-0988045-B1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NIELSEN PETER EIGIL (DK) | 2006-02-08 | — | — | EP | disclosed |
| US-6972288-B1 | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-12-06 | — | — | US | disclosed |
| US-6632919-B1 | Bind Watson-Crick base pairs in a double helix; specific for thymidine | Nielsen, Peter (DK) | 2003-10-14 | — | — | US | disclosed |
| US-6388061-B1 | INCLUDES RUTHENIUM TRIS(BIPYRIDYL) LABEL BONDED TO THE NITROGEN BASE | DAKO A/S (DK) | 2002-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | MEN1 1703/4885GAA 549/4885KMT2A 506/4885 |
| US-20230331760-A1 | ARYL GLUCOSIDE DERIVATIVE AND USE THEREOF IN DRUG | SLC5A1, SLC5A2, SLC10A1 | MEN1 3513/4885GAA 322/4885KMT2A 3515/4885 |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | ERBB2, EGFR, LANCL2 | MEN1 1703/4885GAA 549/4885KMT2A 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.